Buckley Wealth Management LLC Invests $220,000 in IQVIA Holdings Inc. (NYSE:IQV)

Buckley Wealth Management LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 978 shares of the medical research company’s stock, valued at approximately $220,000.

A number of other institutional investors also recently bought and sold shares of the stock. Banque Cantonale Vaudoise increased its holdings in IQVIA by 0.9% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,244 shares of the medical research company’s stock valued at $1,075,000 after buying an additional 45 shares during the period. Investment Research & Advisory Group Inc. raised its position in shares of IQVIA by 0.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 16,896 shares of the medical research company’s stock worth $3,360,000 after acquiring an additional 54 shares in the last quarter. Penserra Capital Management LLC lifted its stake in shares of IQVIA by 6.1% during the 4th quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company’s stock worth $198,000 after purchasing an additional 56 shares during the last quarter. Homestead Advisers Corp boosted its position in IQVIA by 14.9% during the first quarter. Homestead Advisers Corp now owns 433 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 56 shares in the last quarter. Finally, Lindbrook Capital LLC grew its stake in IQVIA by 8.6% in the first quarter. Lindbrook Capital LLC now owns 736 shares of the medical research company’s stock valued at $146,000 after purchasing an additional 58 shares during the last quarter. 86.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. Truist Financial boosted their price objective on shares of IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Morgan Stanley boosted their target price on IQVIA from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd. Citigroup increased their price target on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. StockNews.com started coverage on shares of IQVIA in a report on Thursday, August 17th. They set a “hold” rating on the stock. Finally, Stifel Nicolaus lifted their target price on shares of IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $252.00.

IQVIA Stock Down 1.1 %

Shares of IQV stock opened at $209.35 on Tuesday. IQVIA Holdings Inc. has a twelve month low of $165.75 and a twelve month high of $241.86. The stock has a market cap of $38.34 billion, a P/E ratio of 36.03, a P/E/G ratio of 2.14 and a beta of 1.37. The stock has a 50 day moving average of $219.91 and a 200 day moving average of $208.03. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 2.16.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.70 billion. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 9.24 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.